Furbush copied and pasted:
"I spoke at length with Punit this week, and I'm going to post parts of the conversation as I have time, it was over an hour, so it will take me some time. Punit feels that the big issues facing stock price right now is that few people are really able to follow what they are doing, having NeoPulse and not pursuing it, doing MCC and T-Cell Lymphoma and not pursuing them, so people dont see what they are doing and understand where the company is going. Why decisions are made etc. 2 trials that are important, Phase2B and TNBC, both will most likely lead to a Registration trial for combination with Keytruda for melanoma, and a combination of IL-12 and a new drug for Phase 1B in TNBC. They have limited resources and are really trying to focus all their attention into these 2 and only these 2"
"Heat Pre-clinical data should be available later this year (I guess late April), Plexxikon the trial is done, but they have not decided if they are proceeding further. We may not see that data. Phase 2B Interim data later this year (I expect at the electroporation conference in Aug/Sept), from the sound of it, they are progressing at a very respectable enrollment pace. He didn't say exactly, but I'd guess 3-4 a month. They are using their Perkins machine that they developed in the screening process. The big key here is that OncoSec is the ONLY company that is doing a trial with patients screened to not respond to Keytruda. So, If they get to the market, and provide a screening that shows who will not respond, there will only be one product that is FDA approved. If they aren't screened then the Dr.s may just use the shotgun approach of some other combination, now it is for the insurance to dictate which is lowest priced/ best bang for the buck. Big point is they will be the only FDA approved treatment for non responders of PD1."
"I think both Heat and Plexxikon will end up in partnerships. The Heat one won't happen till late this year as ONCS will have to pay for part of the trial and they are conserving cash. Plexxikon is the one I am not as confident about, but at least they could pay for the trial if they choose to, from my conversation I don't think Punit knows if that is going to go anywhere either. The first conversation he said "no one would get bonuses" the 2nd time they were "seriously considering" not giving bonuses, so we'll see where that goes. Dr. Pierce is 100% not going to be leaving the company, and is fully engaged in the process. Dr. Adil Daud is still heavily involved in their daily activities."
"I'm putting together a timeline of events that I now believe will happen. I'll post it here once I've got it ordered in what I believe to be an accurate manner. I don't know how many warrants are out there right now, but I know 2 lots of them will expire shortly. Punit has no interest in diluting this year, or at least at this share price. I just listened to him again, and he was rather clear about that. Don't expect it to happen unless the stock price goes up significantly. Both major shareholders (and I don't have there names in front of me) still own all the shares they have bought and are very comfortable with where ONCS is at.
People don't fully understand that ImmunoPulse is not IL-12 delivery, they have the ability to dose any DNA plasmid that they want. They can deliver dozens of plasmids at one time, so this can be a delivery system for other companies that develop DNA plasmids. Punit sounded very confident that they would be successful, which might just be him being a CEO."
"Poor communication: T-Cell Lymphoma trial was shutdown, they never finished enrollment, even though they had responses they shut it down as it wasn't something they wanted to pursue (he gave me a more detailed answer, but that is the gist). This was not PR'd, but no big deal IMO. May pursue it as a monotherapy in the future (so it had good response rates), but they need a better electroporation device to treat efficiently, and limited resources it is better to focus on Melanoma."
"Humorous post
So Punit is speaking and says "So I think your question is why are we undervalued as a company....see I'm making you ask the hard questions", only I hadn't asked any questions. On a serious note, I do have more respect for Punit after this. He relayed some personal stories to me, which I may share later, that show me this guy is dedicated and very personally invested in seeing ONCS be successful."
